Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Michael Blaese

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Gene Therapy

Chemicals & Drugs

Living Beings

Disorders

Physiology

Anatomy

Devices

Gene Transfer Techniques

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Blaese R Michael
What is the status of gene therapy for primary immunodeficiency?
Morgan Richard A; Walker Robert; Carter Charles S; Natarajan Ven; Tavel Jorge A; Bechtel Chris; Herpin Betsy; Muul Linda; Zheng Zhili; Jagannatha Shyla; Bunnell Bruce A; Fellowes Vicki; Metcalf Julia A; Stevens Randy; Baseler Michael; Leitman Susan F; Read Elizabeth J; Blaese R Michael; Lane H Clifford
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.
Okada Takashi; Caplen Natasha J; Ramsey W Jay; Onodera Masafumi; Shimazaki Kuniko; Nomoto Tatsuya; Ajalli Rahim; Wildner Oliver; Morris John; Kume Akihiro; Hamada Hirofumi; Blaese R Michael; Ozawa Keiya
In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Blaese (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Blaese R Michael
What is the status of gene therapy for primary immunodeficiency?
Immunologic research 2007;38(1-3):274-84.
2005: Morgan Richard A; Walker Robert; Carter Charles S; Natarajan Ven; Tavel Jorge A; Bechtel Chris; Herpin Betsy; Muul Linda; Zheng Zhili; Jagannatha Shyla; Bunnell Bruce A; Fellowes Vicki; Metcalf Julia A; Stevens Randy; Baseler Michael; Leitman Susan F; Read Elizabeth J; Blaese R Michael; Lane H Clifford
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.
Human gene therapy 2005;16(9):1065-74.
2004: Okada Takashi; Caplen Natasha J; Ramsey W Jay; Onodera Masafumi; Shimazaki Kuniko; Nomoto Tatsuya; Ajalli Rahim; Wildner Oliver; Morris John; Kume Akihiro; Hamada Hirofumi; Blaese R Michael; Ozawa Keiya
In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
The journal of gene medicine 2004;6(3):288-99.
2003: Yamanaka Ryuya; Tsuchiya Naoto; Yajima Naoki; Honma Junpei; Hasegawa Hitoshi; Tanaka Ryuichi; Ramsey Jay; Blaese R Michael; Xanthopoulos Kleanthis G
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
Journal of neurosurgery 2003;99(4):746-53.
2003: Muul Linda Mesler; Tuschong Laura M; Soenen Sherry Lau; Jagadeesh G Jayashree; Ramsey W Jay; Long Zhifeng; Carter Charles S; Garabedian Elizabeth K; Alleyne Melinna; Brown Margaret; Bernstein Wendy; Schurman Shepherd H; Fleisher Thomas A; Leitman Susan F; Dunbar Cynthia E; Blaese R Michael; Candotti Fabio
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.
Blood 2003;101(7):2563-9.
2002: Tuschong Laura; Soenen Sherry L; Blaese R Michael; Candotti Fabio; Muul Linda Mesler
Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.
Human gene therapy 2002;13(13):1605-10.
2002: Wolkersdörfer G W; Bornstein S R; Higginbotham J N; Hiroi N; Vaquero J J; Green M V; Blaese R M; Aguilera G; Chrousos G P; Ramsey W J
A novel approach using transcomplementing adenoviral vectors for gene therapy of adrenocortical cancer.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2002;34(6):279-87.
2002: Higginbotham James N; Seth Prem; Blaese R Michael; Ramsey W Jay
The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid.
Human gene therapy 2002;13(1):129-41.
2001: Agbaria R; Candotti F; Kelley J A; Hao Z; Johns D G; Cooney D A; Blaese R M; Ford H
Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.
Biochemical and biophysical research communications 2001;289(2):525-30.
2001: Okada T; Shah M; Higginbotham J N; Li Q; Wildner O; Walbridge S; Oldfield E; Blaese R M; Ramsey W J
AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits.
Gene therapy 2001;8(17):1315-22.
2000: Christensen R; Kolvraa S; Blaese R M; Jensen T G
Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.
Gene therapy 2000;7(23):1971-8.
2000: Walker R E; Bechtel C M; Natarajan V; Baseler M; Hege K M; Metcalf J A; Stevens R; Hazen A; Blaese R M; Chen C C; Leitman S F; Palensky J; Wittes J; Davey R T; Falloon J; Polis M A; Kovacs J A; Broad D F; Levine B L; Roberts M R; Masur H; Lane H C
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.
Blood 2000;96(2):467-74.
2000: Candotti F; Agbaria R; Mullen C A; Touraine R; Balzarini J; Johns D G; Blaese R M
Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer.
Cancer gene therapy 2000;7(4):574-80.
2000: Morris J C; Ramsey W J; Wildner O; Muslow H A; Aguilar-Cordova E; Blaese R M
A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma.
Human gene therapy 2000;11(3):487-503.
1999: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Habib N A
Human gene marker/therapy clinical protocols.
Human gene therapy 1999;10(18):3067-123.
1999: Wildner O; Blaese R M; Morris J C
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Human gene therapy 1999;10(16):2679-87.
1999: Wildner O; Blaese R M; Candotti F
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Cancer research 1999;59(20):5233-8.
1999: Candotti F; Facchetti F; Blanzuoli L; Stewart D M; Nelson D L; Blaese R M
Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations.
Gene therapy 1999;6(6):1170-4.
1999: Caplen N J; Higginbotham J N; Scheel J R; Vahanian N; Yoshida Y; Hamada H; Blaese R M; Ramsey W J
Adeno-retroviral chimeric viruses as in vivo transducing agents.
Gene therapy 1999;6(3):454-9.
1999: Wildner O; Morris J C; Vahanian N N; Ford H; Ramsey W J; Blaese R M
Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.
Gene therapy 1999;6(1):57-62.
1999: Felzmann T; Ramsey W J; Blaese R M
Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer.
Cancer letters 1999;135(1):1-10.
1999: Wildner O; Blaese R M; Morris J C
Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.
Cancer research 1999;59(2):410-3.
1999: Candotti F; Onodera M; Knazek R A; Blaese R M
Retroviral-mediated transfer and expression of the common gamma chain into human hematopoietic progenitors.
Acta haematologica 1999;101(2):106-10.
1999: Onodera M; Nelson D M; Sakiyama Y; Candotti F; Blaese R M
Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Acta haematologica 1999;101(2):89-96.
1998: Touraine R L; Ishii-Morita H; Ramsey W J; Blaese R M
The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.
Gene therapy 1998;5(12):1705-11.
1998: Touraine R L; Vahanian N; Ramsey W J; Blaese R M
Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions.
Human gene therapy 1998;9(16):2385-91.
1998: Walker R E; Carter C S; Muul L; Natarajan V; Herpin B R; Leitman S F; Klein H G; Mullen C A; Metcalf J A; Baseler M; Falloon J; Davey R T; Kovacs J A; Polis M A; Masur H; Blaese R M; Lane H C
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.
Nature medicine 1998;4(7):852-6.
1998: Kohn D B; Hershfield M S; Carbonaro D; Shigeoka A; Brooks J; Smogorzewska E M; Barsky L W; Chan R; Burotto F; Annett G; Nolta J A; Crooks G; Kapoor N; Elder M; Wara D; Bowen T; Madsen E; Snyder F F; Bastian J; Muul L; Blaese R M; Weinberg K; Parkman R
T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.
Nature medicine 1998;4(7):775-80.
1998: Wildner O; Candotti F; Krecko E G; Xanthopoulos K G; Ramsey W J; Blaese R M
Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression.
Gene therapy 1998;5(5):684-91.
1998: Ramsey W J; Caplen N J; Li Q; Higginbotham J N; Shah M; Blaese R M
Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors.
Biochemical and biophysical research communications 1998;246(3):912-9.
1998: Okada T; Ramsey W J; Munir J; Wildner O; Blaese R M
Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex.
Nucleic acids research 1998;26(8):1947-50.
1998: Onodera M; Nelson D M; Yachie A; Jagadeesh G J; Bunnell B A; Morgan R A; Blaese R M
Development of improved adenosine deaminase retroviral vectors.
Journal of virology 1998;72(3):1769-74.
1998: Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity G J; Blaese R M; Sakiyama Y
Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
Blood 1998;91(1):30-6.
1998: Candotti F; Blaese R M
Gene therapy of primary immunodeficiencies.
Springer seminars in immunopathology 1998;19(4):493-508.
1997: Felzmann T; Ramsey W J; Blaese R M
Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1.
Gene therapy 1997;4(12):1322-9.
1997: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Boucher R C
Human gene marker/therapy clinical protocols.
Human gene therapy 1997;8(18):2301-38.
1997: Ram Z; Culver K W; Oshiro E M; Viola J J; DeVroom H L; Otto E; Long Z; Chiang Y; McGarrity G J; Muul L M; Katz D; Blaese R M; Oldfield E H
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.
Nature medicine 1997;3(12):1354-61.
1997: Jensen T G; Sullivan D M; Morgan R A; Taichman L B; Nussenblatt R B; Blaese R M; Csaky K G
Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients.
Human gene therapy 1997;8(17):2125-32.
1997: Candotti F; Oakes S A; Johnston J A; Giliani S; Schumacher R F; Mella P; Fiorini M; Ugazio A G; Badolato R; Notarangelo L D; Bozzi F; Macchi P; Strina D; Vezzoni P; Blaese R M; O'Shea J J; Villa A
Structural and functional basis for JAK3-deficient severe combined immunodeficiency.
Blood 1997;90(10):3996-4003.
1997: Onodera M; Yachie A; Nelson D M; Welchlin H; Morgan R A; Blaese R M
A simple and reliable method for screening retroviral producer clones without selectable markers.
Human gene therapy 1997;8(10):1189-94.
1997: Fenjves E S; Schwartz P M; Blaese R M; Taichman L B
Keratinocyte gene therapy for adenosine deaminase deficiency: a model approach for inherited metabolic disorders.
Human gene therapy 1997;8(8):911-7.
1997: Ishii-Morita H; Agbaria R; Mullen C A; Hirano H; Koeplin D A; Ram Z; Oldfield E H; Johns D G; Blaese R M
Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment.
Gene therapy 1997;4(3):244-51.
1996: Oakes S A; Candotti F; Johnston J A; Chen Y Q; Ryan J J; Taylor N; Liu X; Hennighausen L; Notarangelo L D; Paul W E; Blaese R M; O'Shea J J
Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways.
Immunity 1996;5(6):605-15.
1996: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Tiberghien P
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(18):2287-313.
1996: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Aebischer P
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(13):1621-47.
1996: Mullen C A; Snitzer K; Culver K W; Morgan R A; Anderson W F; Blaese R M
Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector.
Human gene therapy 1996;7(9):1123-9.
1996: Candotti F; Oakes S A; Johnston J A; Notarangelo L D; O'Shea J J; Blaese R M
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.
The Journal of experimental medicine 1996;183(6):2687-92.
1996: Candotti F; Johnston J A; Puck J M; Sugamura K; O'Shea J J; Blaese R M
Retroviral-mediated gene correction for X-linked severe combined immunodeficiency.
Blood 1996;87(8):3097-102.
1995: Blaese R M
Steps toward gene therapy: 2. Cancer and AIDS.
Hospital practice (1995) 1995;30(12):37-45.
1995: Blaese R M
Steps toward gene therapy: 1. The initial trials.
Hospital practice (1995) 1995;30(11):33-40.
1995: Blaese R M; Culver K W; Miller A D; Carter C S; Fleisher T; Clerici M; Shearer G; Chang L; Chiang Y; Tolstoshev P; Greenblatt J J; Rosenberg S A; Klein H; Berger M; Mullen C A; Ramsey W J; Muul L; Morgan R A; Anderson W F
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Science (New York, N.Y.) 1995;270(5235):475-80.
1995: Ramsey W J; Mullen C A; Blaese R M
Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9 Suppl 1():S70.
1995: Bunnell B A; Muul L M; Donahue R E; Blaese R M; Morgan R A
High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(17):7739-43.
1995: Oshiro E M; Viola J J; Oldfield E H; Walbridge S; Bacher J; Frank J A; Blaese R M; Ram Z
Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells.
Cancer gene therapy 1995;2(2):87-95.
1995: Oldfield E H; Ram Z; Chiang Y; Blaese R M
Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study.
Human gene therapy 1995;6(1):55-85.
1994: Ram Z; Walbridge S; Shawker T; Culver K W; Blaese R M; Oldfield E H
The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats.
Journal of neurosurgery 1994;81(2):256-60.
1994: Ram Z; Walbridge S; Oshiro E M; Viola J J; Chiang Y; Mueller S N; Blaese R M; Oldfield E H
Intrathecal gene therapy for malignant leptomeningeal neoplasia.
Cancer research 1994;54(8):2141-5.
1994: Agbaria R; Mullen C A; Hartman N R; Cooney D A; Hao Z; Blaese R M; Johns D G
Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction.
Molecular pharmacology 1994;45(4):777-82.
1994: Mullen C A; Coale M M; Lowe R; Blaese R M
Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.
Cancer research 1994;54(6):1503-6.
1994: Ram Z; Walbridge S; Heiss J D; Culver K W; Blaese R M; Oldfield E H
In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.
Journal of neurosurgery 1994;80(3):535-40.
1994: Kotani H; Newton P B; Zhang S; Chiang Y L; Otto E; Weaver L; Blaese R M; Anderson W F; McGarrity G J
Improved methods of retroviral vector transduction and production for gene therapy.
Human gene therapy 1994;5(1):19-28.
1994: Blaese R M; Ishii-Morita H; Mullen C; Ramsey J; Ram Z; Oldfield E; Culver K
In situ delivery of suicide genes for cancer treatment.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1190-3.
1993: Mullen C A; Anderson K D; Blaese R M
Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases.
Blood 1993;82(10):2961-6.
1993: Fleisher T A; Blaese R M
New approaches in the therapy of immunodeficiency.
Allergy proceedings : the official journal of regional and state allergy societies 1993;14(6):409-11.
1993: Blaese R M; Mullen C A; Ramsey W J
Strategies for gene therapy.
Pathologie-biologie 1993;41(8):672-6.
1993: Cornetta K; Nguyen N; Morgan R A; Muenchau D D; Hartley J W; Blaese R M; Anderson W F
Infection of human cells with murine amphotropic replication-competent retroviruses.
Human gene therapy 1993;4(5):579-88.
1993: Ram Z; Culver K W; Walbridge S; Frank J A; Blaese R M; Oldfield E H
Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors.
Journal of neurosurgery 1993;79(3):400-7.
1993: Blaese R M; Culver K W; Chang L; Anderson W F; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Human gene therapy 1993;4(4):521-7.
1993: Oldfield E H; Ram Z; Culver K W; Blaese R M; DeVroom H L; Anderson W F
Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.
Human gene therapy 1993;4(1):39-69.
1993: Blaese R M
Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Pediatric research 1993;33(1 Suppl):S49-53; discussion S53-5.
1993: Ram Z; Culver K W; Walbridge S; Blaese R M; Oldfield E H
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
Cancer research 1993;53(1):83-8.
1992: Blaese R M; Culver K W; Ishii H; Oldfield E H; Ram Z; Wallbridge S
Brain tumor treatment: significant contributions.
Science (New York, N.Y.) 1992;258(5090):1960.
1992: Mullen C A; Coale M M; Levy A T; Stetler-Stevenson W G; Liotta L A; Brandt S; Blaese R M
Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.
Cancer research 1992;52(21):6020-4.
1992: Culver K W; Ram Z; Wallbridge S; Ishii H; Oldfield E H; Blaese R M
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.
Science (New York, N.Y.) 1992;256(5063):1550-2.
1992: Mullen C A; Kilstrup M; Blaese R M
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(1):33-7.
1992: Blaese R M; Culver K W
Gene therapy for primary immunodeficiency disease.
Immunodeficiency reviews 1992;3(4):329-49.
1991: Blaese R M
Progress toward gene therapy.
Clinical immunology and immunopathology 1991;61(2 Pt 2):S47-55.
1991: Culver K; Cornetta K; Morgan R; Morecki S; Aebersold P; Kasid A; Lotze M; Rosenberg S A; Anderson W F; Blaese R M
Lymphocytes as cellular vehicles for gene therapy in mouse and man.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3155-9.
1991: Culver K W; Osborne W R; Miller A D; Fleisher T A; Berger M; Anderson W F; Blaese R M
Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer.
Transplantation proceedings 1991;23(1 Pt 1):170-1.
1991: Blaese R M; Culver K W
Prospects for gene therapy of human disease.
Allergologia et immunopathologia 1991;19(1):25-8.
1991: Morecki S; Karson E; Cornetta K; Kasid A; Aebersold P; Blaese R M; Anderson W F; Rosenberg S A
Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII 1991;32(6):342-52.
1991: Culver K W; Anderson W F; Blaese R M
Lymphocyte gene therapy.
Human gene therapy 1991;2(2):107-9.
1990: Wright J J; Wagner D K; Blaese R M; Hagengruber C; Waldmann T A; Fleisher T A
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features.
Blood 1990;76(10):2046-51.
1990: Kasid A; Morecki S; Aebersold P; Cornetta K; Culver K; Freeman S; Director E; Lotze M T; Blaese R M; Anderson W F
Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(1):473-7.
1990: Cornetta K; Moen R C; Culver K; Morgan R A; McLachlin J R; Sturm S; Selegue J; London W; Blaese R M; Anderson W F
Amphotropic murine leukemia retrovirus is not an acute pathogen for primates.
Human gene therapy 1990;1(1):15-30.
1990: Culver K W; Morgan R A; Osborne W R; Lee R T; Lenschow D; Able C; Cornetta K; Anderson W F; Blaese R M
In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys.
Human gene therapy 1990;1(4):399-410.
1989: Springett G M; Moen R C; Anderson S; Blaese R M; Anderson W F
Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent.
Journal of virology 1989;63(9):3865-9.
1989: Kohn D B; Mitsuya H; Ballow M; Selegue J E; Barankiewicz J; Cohen A; Gelfand E; Anderson W F; Blaese R M
Establishment and characterization of adenosine deaminase-deficient human T cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(11):3971-7.
1989: Kohn D B; Anderson W F; Blaese R M
Gene therapy for genetic diseases.
Cancer investigation 1989;7(2):179-92.
1988: Skolik S A; Palestine A G; Blaese R M; Nussenblatt R B; Hess R A
Treatment of experimental autoimmune uveitis in the rat with systemic succinylacetone.
Clinical immunology and immunopathology 1988;49(1):63-71.
1988: Eglitis M A; Kohn D B; Moen R C; Blaese R M; Anderson W F
Infection of human hematopoietic progenitor cells using a retroviral vector with a xenotropic pseudotype.
Biochemical and biophysical research communications 1988;151(1):201-6.
1988: Eglitis M A; Kantoff P W; Kohn D B; Karson E; Moen R C; Lothrop C D; Blaese R M; Anderson W F
Retroviral-mediated gene transfer into hemopoietic cells.
Advances in experimental medicine and biology 1988;241():19-27.
1987: Wright J J; Birx D L; Wagner D K; Waldmann T A; Blaese R M; Fleisher T A
Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection.
The New England journal of medicine 1987;317(24):1516-20.
1987: Hess R A; Tschudy D P; Blaese R M
Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(9):2845-9.
1986: Anderson W F; Kantoff P; Eglitis M; McLachlin J; Karson E; Zwiebel J; Nienhuis A; Karlsson S; Blaese R M; Kohn D
Gene transfer and expression in nonhuman primates using retroviral vectors.
Cold Spring Harbor symposia on quantitative biology 1986;51 Pt 2():1073-81.
1982: Tschudy D P; Hess R A; Frykholm B C; Blaese R M
Immunosuppressive activity of succinylacetone.
The Journal of laboratory and clinical medicine 1982;99(4):526-32.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Michael Blaese

Research Profile (preview)

Procedures

Chemicals & Drugs

Living Beings

Disorders

Physiology

Anatomy

Devices

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Michael Blaese (preview)

All Publications